MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.810
+0.050
+1.81%
After Hours: 2.790 -0.02 -0.71% 16:00 12/06 EST
OPEN
2.770
PREV CLOSE
2.760
HIGH
2.860
LOW
2.705
VOLUME
4.08M
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
2.705
MARKET CAP
365.24M
P/E (TTM)
-0.9940
1D
5D
1M
3M
1Y
5Y
Why Is Clovis (CLVS) Down 32% Since Last Earnings Report?
Zacks.com · 3d ago
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
Zacks.com · 5d ago
Top 10 deletions to the MSCI US Small Cap 1750 Index during semiannual shuffle
During the semiannual review, Clovis Oncology (NASDAQ:CLVS), Maastercraft Boat (NASDAQ:MCFT), Asana (NYSE:ASAN), Five9 (NASDAQ:FIVN), Upstart (NASDAQ:UPST), Passage Bio (OTC:PBIO), American Vanguard (NYSE:AVD), Brightcove (NASDAQ:BCOV), 22nd Century (NASDA...
Seekingalpha · 11/12 20:07
Top 10 deletions from the MSCI US Investable Market 2500 Index during semi-annual rejig
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm
Seekingalpha · 11/12 18:34
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag
Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.
Zacks · 11/04 10:46
Clovis reports slight decrease in Q3 Rubraca sales due to pandemic; shares down 7%
Clovis' (NASDAQ:CLVS) Q3 2021 earnings miss was due in part to a decline in sales of Rubraca caused (rucaparib) by the COVID-19 pandemic. Shares are down 7% premarket. Rubraca revenue declined 2%
Seekingalpha · 11/03 13:18
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
Zacks.com · 11/03 13:15
Clovis Oncology Q3 EPS $(0.56) Misses $(0.48) Estimate, Sales $37.92M Miss $39.09M Estimate
Clovis Oncology (NASDAQ:CLVS) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 37.08 percent increase over losses of $(0.89) per share from
Benzinga · 11/03 12:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLVS. Analyze the recent business situations of Clovis Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
20.00%Buy
40.00%Hold
40.00%Under-perform
0.00%Sell
Analyst Price Target
The average CLVS stock price target is 5.94 with a high estimate of 8.00 and a low estimate of 4.750.
High8.00
Average5.94
Low4.750
Current 2.810
EPS
Actual
Estimate
-0.82-0.61-0.41-0.20
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 270
Institutional Holdings: 69.99M
% Owned: 53.85%
Shares Outstanding: 129.98M
TypeInstitutionsShares
Increased
57
10.22M
New
24
763.93K
Decreased
37
3.33M
Sold Out
26
1.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.96%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
Non-Executive Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers - Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/Chief Scientific Officer
Thomas Harding
Executive Vice President/General Counsel
Paul Gross
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward Mckinley
Independent Director
Ronit Simantov
Independent Director
Thorlef Spickschen
No Data
  • All
  • Financials
  • Insiders
More
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT).

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.